

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

FERGUSON et al

Atty. Ref.: 39-148

Serial No.: 08/307,640

Group Art Unit: 1644

Filed: September 16, 1994

Examiner: Cunningham, T.

For: **WOUND HEALING AND TREATMENT OF FIBROTIC  
DISORDERS**

\* \* \* \* \*

March 8, 2000

AMENDMENT UNDER RULE 116

O.K. to  
ENR 1287  
P.N.  
4-3-00

Hon. Commissioner of Patents  
and Trademarks  
Washington, DC 20231

Sir:

This is in response to the Office Action dated August 16, 1999, in the above matter, a Notice of Appeal having been filed February 16, 2000. The following comments are offered.

REMARKS

Reconsideration of this application is respectfully requested.

In item (2) of the Office Action, the Examiner suggests that the claims be limited so as to exclude the presence of fibrotic growth factors such as TGF- $\beta$ 1 and TGF- $\beta$ 2 "in order to expedite examination". Respectfully, statutory basis for the suggestion is not seen. While TGF- $\beta$ 1 and TGF- $\beta$ 2 are known to be fibrotic (and therefore antagonistic to the anti-fibrotic effects of